Intrathecal Bupivacaine-Dexmedetomidine Compared to Intrathecal Bupivacaine-Neostigmine in Elective Caesarean Sections, Randomized Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Time started from the end of intrathecal injection till achievement of a bilateral sensory block at T10
研究概览
简要总结
Spinal anesthesia is an established technique used in obstetric surgeries, It provides adequate analgesia both intra and post-operative and also avoids complications associated with general anesthesia for mother and fetus. The quality of spinal anesthesia has been reported to be improved by using additives Dexmedetomidine is a highly selective α2-adrenoreceptor agonist that has been introduced to anesthesia. It produces dose-dependent sedation, anxiolysis, and analgesia without respiratory depression. Neostigmine is an anticholinesterase agent, which inhibits the hydrolysis of acetylcholine by competing with acetylcholine for attachment to acetyl cholinesterase; administration of Neostigmine through intrathecal route apparently activates the descending pain inhibitory system that relies on spinal cholinergic interneuron. Study conducted to evaluate whether neostigmine given by intrathecal route with 0.5% hyperbaric bupivacaine for spinal anesthesia can provide prolongation of sensory blockade duration as effective as dexmedetomidine given by the same route and in compination with same drug with lower cost, more stable hemodynamics and comparable side effects. After obtaining Institutional Ethics Committee approval and written informed consent,54 patients American Society of Anesthesiologist (ASA) physical status I and II were enrolled into the study and were randomlyassigned into 3 groups. Group 1were received 10 mg (2ml) hyperbaric bupivacaine and 0.1 ml (10 μg) DXM and 0.1 ml normal saline, Group 2 were received 10 mg (2ml) hyperbaric bupivacaine and 0.1 ml (50 μg) neostigmine and 0.1 ml normal saline and Group 3were received 10 mg (2ml) hyperbaric bupivacaine and 0.2 ml normal saline as control.
The investigators measured the time to reach T4 dermatome sensory block, peak sensory level, Time to reach Bromage 3 motor block, the regression time for sensory and motor block, also the investigators measured hemodynamic, sedation score, visual analogue score, any complications occurred and Apgar score for fetus during blockade and the investigators assessed the duration of pain relief .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years(Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •ASA physical status I and II patients
- •Age: 18 - 40 years
- •Height 150 - 170 cm
- •Weight 70 - 110 kg.
排除标准
- •Patient refusal
- •Cardiac diseases as ( ischemic heart disease, severe valvular stenosis, pulmonary hypertension, uncontrolled arrhythmias )
- •Severe labile hypertension BP more than 160 / 100 )
- •Raised intracranial pressure or pre-existing neurological disorders, such as multiple sclerosis.
- •Patients with coagulopathy: platelets < 100,000 INR ≥ 1.3 or therapeutic use of anti-coagulants.
- •Inability to communicate and understand the aim of the project.
- •Patients with history of allergic reaction to LA, DXM or Neostigmine.
- •Skin infection at injection site or systemic bacteremia.
- •Failure of the block and need for general anesthesia.
研究组 & 干预措施
DEXMEDETOMIDINE
Group 1 ( 18 patients ) were received 10 mg (2ml) hyperbaric bupivacaine and 0.1 ml (10 μg) DXM and 0.1 ml normal saline.
干预措施: DEXMEDETOMIDINE (Drug)
Neostigmine
Group 2( 18 patients ) were received 10 mg (2ml) hyperbaric bupivacaine and 0.1 ml (50 μg) neostigmine and 0.1 ml normal saline.
干预措施: Neostigmine (Drug)
Bupivacaine
Group 3 ( 18 patients ) were received 10 mg (2ml) hyperbaric bupivacaine and 0.2 ml normal saline as control.
干预措施: Bupivacaine (Drug)
结局指标
主要结局
Time started from the end of intrathecal injection till achievement of a bilateral sensory block at T10
时间窗: 90 seconds
assessed by a pin prick needle from caudal to cephalic direction
次要结局
未报告次要终点
研究者
Reham Ali Abdelhaleem Abdelrahman
Anesthesia lecturer M.D.
Cairo University
